2017 was another good year for Medistim, with continued growth and profitability. Sales for the group in 2017 ended at 301.5 MNOK (268.1 MNOK), a 12.5 % growth. In Medistim’s largest market, USA, there was a growth of 15.0 %. Asia and the rest of the world had a growth of 8.7 % and 23.4 % respectively.
We have further strengthened our position within cardiac bypass surgery, in particular in our most important market USA, where we now have achieved a market penetration of 20% measured as the share of bypass procedures done with Medistim’s devices. In addition, we have strengthened our position in Europe through the establishment of our direct operation in Spain.
Download the full report here: